Kornimate/medical-research-clean huggingface dataset:
dietary protein requirements in hemodialysis patients

Conditions: Chronic Renal Failure; End-Stage Renal Disease

Summary: the primary purpose of this study is to assess dietary protein requirements in clinically stable maintenance hemodialysis (mhd) patients. it is hypothesized that the average dietary protein intake (dpi) that will maintain nitrogen balance is 1.00 g protein/kg/day, but that a safe intake that maintains balance in almost all mhd patients is about 1.25g protein/kg/day.

a high proportion of maintenance hemodialysis (mhd) patients have protein-energy malnutrition (pem) which is a powerful predictor of high morbidity and mortality. although inflammation may contribute to pem, low dietary protein intake (dpi) is often a contributing factor. the usual dpi of mhd patients in about 1.0 g protein/kg/day, whereas expert groups recommend = 1.20 g protein/kg/day. however, these recommendations are based upon few studies, often of insufficient duration, that were usually carried out with obsolete types of dialysis therapy. we will examine the response to different levels of dietary protein intake (0.6-1.3 g protein/kg/day) under classical balance techniques with carefully controlled dietary intakes, living, conditions, and collection of nitrogen outputs and carefully measured nitrogen intakes and outputs.

Eligibility criteria:
inclusion criteria: * ages from 30 years through 65 years * both men and women and all ethnic and racial groups * treatment with mhd for 6 months or greater * hemoglobin of at least 11 g/dl * neurological examination indicating no severe neuropathy * a negative test for peripheral arterial occlusive disease exclusion criteria: * obesity: body weight greater than \>115% of standard * history of active cancer other than basal cell carcinoma * symptomatic severe ischemic heart disease, uncontrolled serious dysrhythmias, uncontrolled congestive heart failure, poorly controlled hypertension, severe musculoskeletal disease, arthritis or amputations of the lower extremities * insulin dependent or insulin independent diabetes mellitus * severe lung or liver disease, uncontrolled asthma, active vasculitis. severe chronic infection or any other acute or chronic inflammatory or catabolic illnesses * psychosis, inability to give informed consent, evidence that patient will not comply with study protocol * alcohol or other recreational drug abuse * patients who received l-carnitine or anabolic hormones within the previous 6 months * pregnancy * patients who are physically and/or psychologically incapable of undergoing the protocol

Keywords: chronic renal failure end-stage renal disease nitrogen balance dietary protein intake
what are the main themes concerned by the second-line smur 67, known as reinforcements, in the bas-rhin sector

Conditions: Reasons for Emergency Calls

Summary: in this study the investigators wish to evaluate the possibility of anticipating the requests for smur reinforcement within the samu67. the studied population concerns each patient having benefited from an smur at the time of his pre-hospital care. the investigators expect from this study an improvement of the assumption of responsibility of the patients in the future with optimization of the delay of sending of an smur when this one is necessary.


Eligibility criteria:
inclusion criteria: * adult patients having benefited from a pre-hospital smur over the period from 01/01/2020 to 14/07/2020. * no opposition from the patient or his parental authority to the re-use of his medical data for scientific research. exclusion criteria: - presence of opposition from the patient or his parental authority to the re-use of his medical data for scientific research purposes.

Keywords: emergency calls samu67 smur
evaluation of the survival of inflamed mature single rooted teeth

Conditions: Regeneration

Summary: the majority of articles present in literature concerning the enrollment of tissue engineering in the field of root canal treatment is concerned with the treatment of affected teeth with immature apex, after proper systematic search online, only 4 articles where found that are dealing with the treatment of teeth with mature apex. these 4 studies are case reports. none of these studies has been a randomized clinical trial, the gold standard of interventional trials resulting in the highest level of evidence that contributes effectively in the clinical decision-making process as to the best intervention for the patient's condition providing the most effective clinical outcomes for the satisfaction of the patient. since that the triad of regenerative endodontics are the key of success of any attempt to regenerate pulp, 2 different maneuvers shall be done in this study.

preservation of the natural dentition had always been a primary objective in endodontic practice. when the pulp is diseased or requires removal for restorative reasons, it is replaced with an artificial filling material during conventional root canal treatment. root canal treatment has lots of drawbacks, starting with different iatrogenic errors during endodontic procedures, weakening of remaining tooth structure which might affect the tooth survival. also root canal treated teeth require the placement of a post and core, which itself is doubtful whether it increases fracture resistance of the tooth or it weakens it. the most important drawback is that the survival of affected pulp is hindered by the conventional root canal treatment. thus a new treatment approach was introduced utilizing the body ability to regenerate, called pulp regeneration. regeneration was first introduced in the dental field as a solution for immature apex treatment, due to difficulties encountered during its conventional root canal treatment. here the pulp regeneration shall be used on vital mature teeth to increase the survival rate of the affected teeth.

Eligibility criteria:
inclusion criteria: * patients who are free from any physical or mental handicapping condition with no underlying systemic diseases. * non-pregnant females * single canalled teeth. * patients having vital, mature, single rooted teeth, clinical evidence of pulpitis and apical periodontitis. * positive patient/guardian compliance for participation in the study. exclusion criteria: * any known sensitivity or adverse reactions to medicaments or pharmaceuticals necessary to complete the trial. * non-restorable coronal portion of teeth involved in the trial. * non vital teeth * immature teeth * traumatized teeth * radiographic evidence of external or internal root resorption. * single rooted teeth with multiple canals.
influence of escitalopram on fear conditioning

Conditions: Fear Conditioning

Summary: the purpose of the study is to learn how differences in learning under mildly-stressful circumstances may be changed by taking an antidepressant medication. this medication is called lexapro (escitalopram). the investigators will also examine the impact of any anxiety, depression, and stress related symptoms on learning processes. the investigators will also look at the response of these symptoms to lexapro.


Eligibility criteria:
inclusion criteria: 1. male or female outpatients 18 to 75 years of age 2. must have no current dsm-iv axis i diagnosis as measured by the scid (structured clinical interview for dsm-iv-tr axis 1 disorders) with a trained study investigator. past history of anxiety disorders, major depressive episodes or substance abuse disorders at least six months prior to baseline are not exclusionary. exclusion criteria: 1. patients will be excluded from entry into the study for current serious medical conditions or other conditions deemed likely to result in surgery or hospitalization. 2. patients with a history of trauma resulting in head injury related seizures, or with epilepsy (except a prior history of febrile seizures of infancy which are not exclusionary). 3. pregnant or lactating women or those of childbearing potential not using medically accepted forms of contraception will be excluded. 4. concurrent use of other antidepressants, benzodiazepines or antipsychotic medications. 5. patients with a history of hypersensitivity to escitalopram are excluded. 6. individuals must have discontinued mao inhibitors more than 14 days before starting study drug. 7. additional contraindicated drugs during the study are pimozide, furazolidine, isocarboxazid, lazabemide, and st. john's wort. 8. participants meeting dsm-iv or scid criteria for a substance use disorder in the last six months other than nicotine dependence and those with a positive toxicology screen at baseline consistent with evidence of current substance abuse or dependence as determined by clinical interview. 9. a lifetime history of bipolar or any psychotic disorder is excluded. 10. current claustrophobia is exclusionary. 11. patients currently taking any narcotic will be excluded.
study to investigate the efficacy and safety of dupilumab administered with topical corticosteroids (tcs) in participants ≥6 to <12 years with severe atopic dermatitis (ad)

Conditions: Dermatitis, Atopic

Summary: the main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (tcs) in participants ≥6 years to \<12 years of age with severe atopic dermatitis (ad). the secondary objective is to assess the safety of dupilumab administered concomitantly with tcs in patients ≥6 years to \<12 years of age with severe ad.


Eligibility criteria:
key inclusion criteria: 1. diagnosis of ad according to the american academy of dermatology consensus criteria (eichenfield 2003) at screening visit 2. chronic ad diagnosed at least 1 year prior to the screening visit 3. iga = 4 at screening and baseline visits 4. easi ≥21 at the screening and baseline visits 5. bsa ≥15% at screening and baseline visits 6. documented recent history (within 6 months before the baseline visit) of inadequate response to topical ad medication(s) 7. at least 11 (of a total of 14) applications of a stable dose of topical emollient (moisturizer) twice daily during the 7 consecutive days immediately before the baseline visit key exclusion criteria: 1. participation in a prior dupilumab clinical study 2. treatment with a systemic investigational drug before the baseline visit 3. treatment with a topical investigational drug within 2 weeks prior to the baseline visit 4. treatment with crisabarole within 2 weeks prior to the baseline visit 5. history of important side effects of medium potency topical corticosteroids (e.g, intolerance to treatment, hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed by the investigator or patient's treating physician 6. treatment with a topical calcineurin inhibitor (tci) within 2 weeks prior to the baseline visit 7. having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment: 1. immunosuppressive/immunomodulating drugs (e.g, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon gamma, janus kinase inhibitors, azathioprine, methotrexate, etc.) 2. phototherapy for ad 8. treatment with biologics, as follows: 1. any cell-depleting agents including but not limited to rituximab: within 6 months before the baseline visit, or until lymphocyte and cd 19+ lymphocyte count returns to normal, whichever is longer 2. other biologics: within 5 half-lives (if known) or 16 weeks before the baseline visit, whichever is longer 9. treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit 10. body weight \<15 kg at baseline note: other inclusion/ exclusion criteria apply

Keywords: eczema
effects of osteostrong vs. individually adapted and combined training on bone health

Conditions: Osteoporosis; Osteopenia; Bone Density, Low; Bone Loss

Summary: the aim of this clinical trial is to investigate the effect of the osteostrong training method and the individually adapted and combined training on the bone health of older women with high fracture risk. additionally, the aim is also to explore the participants' experiences of each training method. participants will be randomised to either treatment arm a (osteostrong) or treatment arm b (individually adapted and combined training). participants in both groups will train for nine months. treatment arm a will train individually once a week and treatment arm b will train in a group twice a week. both groups will have a training instructor who will supervise and give training instructions. researchers will compare the groups to see the effects of the training methods on the participants' bone health among other outcome measures. the participants will be tested at baseline and post-intervention (9 months later).


Eligibility criteria:
inclusion criteria: * woman, 65-79 years old. * vaccinated against covid-19. * be able to participate in nine months of training. * untreated with osteoporosis-medications, or have an ongoing treatment since at least one year back. exclusion criteria: * ongoing treatment with osteoporosis-medications with an onset within a year, or a previous treatment which was terminated within the last five years. * ongoing treatment with osteoporosis-medications that has been delayed for more than eight months for denosumab, or more than 18 months for bisphosphonates. * vertebral fracture, that have been diagnosed within three months. * vertebral fracture or hip fracture, that have not previously been treated with osteoporosis-medications or been assessed by a physician. * bilateral hip replacements. * symptomatic disc herniation, inguinal herniation or umbilical herniation. * untreated hypertension. * other diseases that can affect the results and participation in the study: malignant diseases, muscle dystrophy, secondary osteoporosis, or other conditions that would hinder study participation. * ongoing treatment with oral cortisone pills (≥ 5 mg prednisolone). * conditions that hinders the conduction of impact microindentation with osteoprobe: large edema, skin infection, allergy towards local anaesthetics. * ongoing or previous training (within the last year) at osteostrong.

Keywords: osteoporosis osteopenia bone mineral density bone density physical activity strength training isometric training
correlation study between clinical phenotype and pathology of type 2 diabetic nephropathy

Conditions: Diabetic Kidney Disease

Summary: with the rapid increase of diabetic nephropathy worldwide, type 2 diabetes mellitus(dm) is the leading cause of end-stage renal disease(esrd). pathological types of diabetic kidney disease(dkd) could be mainly divided into diabetic nephropathy（dn）and non-diabetic renal diseases（ndrd）. there are no accurate renal biopsy indications and standardized operation procedures for type 2 diabetic nephropathy. the clinical stages of type 2 diabetic nephropathy still referred to the mogensen stage of type 1 diabetic nephropathy. thus, our study aim to clarify the differences in clinical phenotype between type 2 dn and type 2 ndrd, analysis the correlation between clinical and pathological features, and offer the criteria for clinical staging and prognosis.


Eligibility criteria:
inclusion criteria: * age≥18, male or female * clinical diagnosed as type 2 diabetes mellitus * the presence of renal impairment including: microalbuminuria or overt proteinuria or renal insufficiency * the renal biopsy was performed with complete renal pathological diagnosis * obtaining the signed informed consent from patients exclusion criteria: * the history of the disease was not complete * clinical diagnosed as other secondary renal diseases * patients with hereditary kidney disease * autoimmune diseases * patients with malignant tumor were expected to survive less than 6 months * pregnancy and lactation

Keywords: diabetic kidney disease (dkd) diabetic nephropathy（dn) non-diabetic renal diseases（ ndrd) clinical-pathological correlations differential diagnosis
full spectrum hemp observational study

Conditions: Acne Vulgaris; Acne Vulgaris Superficial Mixed Comedonal and Inflammatory

Summary: in westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. standard treatment modalities present with high risk morbidities. charlotte's web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

charlotte's web full spectrum hemp blemish product will contain a mere 0.018% thc and will therefor not impart a psychotic affect. hemp has been shown to be well tolerated in humans and has a very acceptable dosage, efficacy and safety profile when topically applied. the fda has labeled hemp as generally regarded as safe (gras) and as such reduces the risk of severe adverse reactions to the subject. benefits of hemp blemish 'cream" is that it has been formulated in such a way as to promote natural skin balance, and may eliminate skin dryness, inflammation, hyperpigmentation, and scaring. the primary objective and endpoint of the study is to obtain total eradication of the blemish eruptions. the secondary objective and endpoints is the continued use of the hemp product will continue to prevent further blemish eruptions and provide other skin benefits especially reducing the propensity to scar.

Eligibility criteria:
inclusion criteria: * male/female * diagnosed acne vulgaris * not on current acne treatment(s) or off current treatment for 2 weeks * 13-70 yrs old exclusion criteria: * not willing to stop current acne treatment(s) * males that present with facial hair * active tb, hiv or hepatitis * pregnant or lactating females

Keywords: blemishes
association of transcranial alternating current stimulation with digital cognitive training for cognitive remediation in older adults

Conditions: Cognitive Dysfunction; Alzheimer Disease; Mild Cognitive Impairment; Cognitive Decline; Frontotemporal Degeneration; Dementia; Dementia, Vascular; Lewy Body Disease; Beta-Amyloid; GFAP; Tau Protein

Summary: background cognitive decline in older adults, especially those who develop mild cognitive impairment and alzheimer's disease, currently has limited options of pharmacological treatments, with modest efficacy. digital cognitive training (dct) and transcranial alternating current stimulation (tacs) are two promising tools for cognitive remediation in this population. in this exploratory study, we investigate feasibility, tolerability and preliminary effects of the association of both interventions in older adults with cognitive complaints. methods older adults with cognitive complaints are being enrolled for this study, which comprises 5 daily sessions of 30 minutes of dct using the brainhq platform while simultaneously receiving theta tacs (6hz, 1.6ma) targeting the left dorsolateral prefrontal cortex.

our goals in this study are: * to investigate the feasibility and safety of transcranial direct current stimulation (tdcs) adjunctive to cognitive training (ct) in a cohort of individuals diagnosed with mild cognitive impairment (mci), subjective cognitive decline or alzheimer's desease in it's initial phase (cdr 1). * to assess the efficacy of this combined intervention in modulating cognitive function, as measured by a comprehensive neuropsychological battery. * to explore the underlying neural mechanisms of this intervention by examining changes in event-related potentials (erps), specifically the n200 and p300 components, which are sensitive to cognitive processes and neural plasticity. * to identify potential peripheral biomarkers in serum that may correlate with cognitive decline and response to the intervention. * to determine whether the combined intervention can induce lasting changes in neurophysiological markers, as assessed by repeated erp measurements. * to examine the relationship between the observed cognitive improvements, alterations in neurophysiological measures, and changes in serum biomarker levels, with the aim of elucidating the biological mechanisms underlying the intervention's effects.

Eligibility criteria:
inclusion criteria: * healthy subjects over 50 years old, with cognitive complaints exclusion criteria: * estimated intelligence quotient \<80 * dependence on psychoactive substances (dsm-v) * severe psychiatric or neurological disorders * uncorrected visual/hearing problems * history of syncope for an unexplained reason or seizure less than a year ago * previous stroke * use of anticoagulants * intracranial metallic prosthesis or cardiac pacemaker * any contraindication to performing tacs

Keywords: tacs nibs transcranial alternate current stimulation mild cognitive impairment mci alzheimer cognition elderly older adults cognitive enhancement
to investigate the impact of analgesic management guided by qnox monitoring on the comfort and prognosis of mechanically ventilated icu patients

Conditions: Pain

Summary: purpose: to explore the effect of analgesic management under the guidance of qnox monitoring on the comfort level and prognosis of patients with mechanical ventilation in icu. method:after admission to icu, the patients were randomly divided into the analgesia group guided by bps（behavioral pain scale） and physiological indicators monitoring and qnox-guided analgesia group (qnox group). sedation and analgesia program after admission to icu (continuous injection pump) : propofol 1.5-4.5mg/kg.h, remifentanil 5-8ug/kg.h, maintain sedation goals rass（richmond agitation-sedation scale）-3 to -4 scores, bps（behavioral pain scale）3 to 4 scores. the researchers worked with the bedside nurse to plan different care procedures, including :1) central venous catheter or arterial catheter puncture; 2) the patient is turned over completely so that the back can be washed and the sheets changed; 3) endotracheal sputum aspiration (patients with intubation or in tracheotomy state ); 4) dressing the wound. primary outcome:value of qnox at bps（behavioral pain scale）≥5 (qnox sensitivity, specificity, positive predictive value and negative predictive value) secondary outcome:to investigate the patient baseline variables that may affect qnox; variables that may influence qnox in relation to critical illness.


Eligibility criteria:
inclusion criteria: 1. patients aged 18 years or older who are undergoing abdominal, orthopedic, ent（ear-nose-throat）, urological, neurosurgical or cardiothoracic surgery and require icu treatment with mechanical ventilation while having an rass（richmond agitation-sedation scale）-3 or -4 score; 2. patients unable to self-assess pain intensity using nrs（numerical pain rating scale）; 3. patients who have provided informed consent. exclusion criteria: 1. \< 18 years of age; 2. pregnant individuals; 3. patients with communication impairments, such as those who have experienced cerebrovascular accidents; 4. a decision to withdraw life-sustaining treatment or an unstable medical condition that disrupts planned routine care.